What is Tasso?
Tasso is a pioneering medical technology firm dedicated to bringing diagnostic testing directly to the patient. By developing innovative, user-friendly devices that facilitate blood collection at home, the company aims to eliminate the barriers associated with traditional clinical visits. This patient-centric approach not only enhances the quality of life for individuals requiring frequent monitoring but also empowers healthcare providers with timely, actionable data. Tasso's market position is defined by its commitment to clinical rigor and its ability to integrate seamlessly into existing healthcare ecosystems, thereby bridging the gap between laboratory precision and home-based convenience.
How much funding has Tasso raised?
Tasso has raised a total of $125.4M across 4 funding rounds:
Grant
$2.3M
Other Financing Round
$6.1M
Series A
$17M
Series B
$100M
Grant (2014): $2.3M, investors not publicly disclosed
Other Financing Round (2019): $6.1M led by Vertical Venture Partners
Series A (2020): $17M, investors not publicly disclosed
Series B (2021): $100M featuring SVB Innovation Fund, RA Capital Management, D. E. SHAW, InCube, and Senvest Capital
Key Investors in Tasso
RA Capital Management
RA Capital Management is a multi-stage investment manager focused on evidence-based investing in public and private healthcare and life science companies, including those developing drugs, medical devices, diagnostics, and research tools.
D. E. SHAW
Founded in 1988, D. E. Shaw is an asset management company specializing in quantitative investing and headquartered in New York.
Senvest Capital
Incorporated in 1968 and located in Montreal, Canada, Senvest Capital operates as a holding company with interests in investment management and direct investing in public securities and private investments.
What's next for Tasso?
With the recent infusion of capital, Tasso is well-positioned to scale its operations and expand its diagnostic portfolio. The strategic focus will likely shift toward accelerating the commercialization of its core technologies and deepening its integration with large-scale healthcare providers and research institutions. As the company navigates this growth phase, it will likely leverage its robust financial backing to enhance its supply chain, invest in further clinical validation, and explore new therapeutic areas. The objective remains clear: to establish home-based diagnostics as the standard of care, ultimately driving a more efficient and equitable healthcare system.
See full Tasso company page
